Welcome to our dedicated page for Cosciens Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The COSCIENS Biopharma Inc. (CSCI) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. COSCIENS files reports such as Form 20-F annual reports and Form 6-K current reports, which include financial statements, management’s discussion and analysis, and press releases on strategic initiatives, clinical programs and capital markets decisions.
Through these filings, investors can review how COSCIENS describes its business as a life sciences company focused on natural, plant-based active ingredients, cosmeceutical, nutraceutical and pharmaceutical products, and diagnostic assets like macimorelin (Macrilen; Ghryvelin) for adult growth hormone deficiency. The filings also discuss the company’s proprietary extraction technologies, its use of Pressurized Gas eXpanded (PGX) Technology, and the evolution of its portfolio following the merger of Aeterna Zentaris and Ceapro.
Key documents available or referenced via SEC filings include quarterly and interim financial statements, risk factor discussions, and detailed commentary on cost structure realignment, restructuring and zero-based budgeting initiatives. Filings also record important capital markets events, such as COSCIENS’ voluntary delisting from the Nasdaq Capital Market via Form 25, while retaining its Toronto Stock Exchange listing and seeking quotation for its shares in the U.S. over-the-counter market under the symbol CSCIF.
Stock Titan’s platform surfaces these filings alongside AI-powered summaries that explain complex sections, highlight changes from prior periods and point out items relevant to CSCI shareholders, such as discussions of Macrilen commercialization, PGX Technology scale-up and strategic program decisions. Users can quickly scan recent 6-K submissions, annual 20-F reports and other key documents to understand COSCIENS’ financial position, strategic direction and regulatory reporting history.
COSCIENS Biopharma Inc. terminates the Form F-1 offering that had registered up to 14,457,831 units with a proposed aggregate offering price of up to $12,000,000.
This Post-Effective Amendment No. 6 deregisters and removes from registration any unsold registered Units, Pre-Funded Units, Common Warrants, Placement Agent Warrants and the underlying Shares as of the amendment's effectiveness.
COSCIENS Biopharma Inc. filed Post-Effective Amendment No. 1 to its Form F-1 to terminate the offering and deregister securities previously registered under Registration No. 333-277115.
The original Registration Statement registered the issuance of up to 633,583 common share purchase warrants and up to 633,583 Shares issuable upon exercise of those Warrants, of which 579,037 Warrants were issued to Shareholders and 54,546 Warrants were issued to Existing Warrant Holders. The amendment terminates the offering in the United States and removes from registration any and all securities remaining unsold as of the effective date of this Post-Effective Amendment.
COSCIENS Biopharma Inc. has filed Post-Effective Amendment No. 6 to its Form F-1 to terminate the offering and remove from registration any unsold securities under Registration Statement No. 333-239019. The original registration, declared effective June 16, 2020, had registered up to 6,177,174 common shares issuable upon exercise of certain warrants. This amendment, signed March 13, 2026, states the Company has terminated the offering and removes all securities remaining unsold as of effectiveness.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.
COSCIENS Biopharma Inc. furnished a Form 6-K that includes its Q3 2025 interim financial materials and related certifications. The filing lists Exhibits 99.1–99.4, covering condensed interim consolidated financial statements for the third quarter of 2025, management’s discussion and analysis, and CEO/CFO certifications under National Instrument 52-109.
The exhibits are incorporated by reference into the company’s existing Form S-8 registration statements and are deemed part of those filings from the date this Form 6-K is furnished. The company also includes forward-looking statements and directs readers to risk factors in its most recent Annual Report on Form 20-F.
COSCIENS Biopharma Inc. furnished a Form 6-K noting it issued a press release with third quarter 2025 results and a strategic update, including a voluntary delisting from the Nasdaq Capital Market while maintaining its listing on the Toronto Stock Exchange.
The press release is attached as Exhibit 99.1 and is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-224737, 333-210561, 333-200834, 333-279844). The filing reiterates forward-looking statement cautions and points investors to existing risk factors in its most recent Form 20-F and other filings.
COSCIENS Biopharma Inc. filed a Form 25 to remove its common shares, with no par value, from listing and/or registration on the Nasdaq Capital Market under Section 12(b) of the Securities Exchange Act of 1934.
The company certifies it has reasonable grounds to believe it meets all requirements for filing this notification, which was signed by Chief Financial Officer Giuliano La Fratta and dated August 26, 2025.
COSCIENS Biopharma Inc. furnished a Form 6-K as a foreign private issuer for August 2025, primarily to provide investors with its second quarter 2025 information package. The filing incorporates Exhibits 99.1 through 99.4 into the company’s existing Form S-8 registration statements, so these Q2 materials become part of the documents used for its equity compensation plans.
The exhibits include condensed interim consolidated financial statements for Q2 2025, management’s discussion and analysis of financial condition and results of operations for the same period, and certifications from the chief executive officer and principal financial officer under Canadian National Instrument 52-109. The report also contains an extensive forward-looking statements section outlining business expectations and key risk areas, and it directs readers to the latest Form 20-F and other SEC filings for additional risk factors.
COSCIENS Biopharma Inc. filed a report describing a press release that covers its second quarter 2025 financial results and a strategic initiatives update. The company plans to voluntarily delist its shares from the Nasdaq Capital Market while keeping its listing on the Toronto Stock Exchange, meaning trading in the United States would move off Nasdaq but the shares would remain listed in Canada. The report also incorporates the press release into several existing Form S-8 registration statements for employee equity plans. Extensive forward-looking statements highlight uncertainties around the company’s technologies, products, business strategy, discontinued research programs, facilities, clinical studies, financial resources, and overall outlook, and direct readers to previously disclosed risk factors in its latest Form 20-F.